Tian Xie

Title: Innovations of Tian Xie in Biomedical Research

Introduction

Tian Xie is a prominent inventor based in Hangzhou, China. He has made significant contributions to the field of biomedical research, particularly in the development of innovative drug delivery systems. With a total of 2 patents, his work focuses on enhancing the efficacy of anti-tumor therapies.

Latest Patents

Tian Xie's latest patents include groundbreaking inventions that aim to improve cancer treatment. The first patent is for a dual-targeting biomimetic liposome that incorporates elemene (ELE) and cabazitaxel (CTX). This innovative liposome formulation is designed to enhance drug delivery, with specific components including 0.15 g to 0.75 g of ELE and 0.015 g to 0.07 g of CTX per 100 mL. The second patent involves a 14-chloro-β-elemene nitric oxide donor derivative, which is aimed at the preparation of anti-tumor drugs. This derivative features a unique structure that includes nitrogen and oxygen atoms, showcasing Tian's expertise in chemical formulations.

Career Highlights

Tian Xie is affiliated with Hangzhou Normal University, where he conducts research and develops his innovative ideas. His academic background and research focus have positioned him as a key figure in the field of drug development. His work not only contributes to scientific knowledge but also has the potential to impact clinical practices in oncology.

Collaborations

Tian collaborates with notable colleagues such as Renren Bai and Xiangyang Ye. These partnerships enhance the research environment and foster innovation in their projects.

Conclusion

Tian Xie's contributions to biomedical research through his patents reflect his commitment to advancing cancer treatment. His innovative approaches in drug delivery systems are paving the way for more effective therapies.